French National Agency For Research On Aids And Viral Hepatitis

This study tested a DNA vaccine in 70 adults with chronic hepatitis B who had undetectable virus levels while on antiviral drugs. The goal was to see if the vaccine could train the immune system to keep the virus under control after stopping medication. Researchers measured how l…

This study tested a once-daily HIV medication (tenofovir-emtricitabine plus efavirenz) in 70 adults with both HIV and tuberculosis. The goal was to see if a simpler, once-daily pill routine could effectively control HIV while being safe for people also being treated for TB. The m…

This study looked at how HIV drugs behave in the body of people starting treatment for the first time. 35 participants took a once-daily combination of atazanavir, ritonavir, tenofovir, and emtricitabine. A special electronic pill bottle (MEMS) recorded when they took their medic…

This study tested two statins, rosuvastatin and pravastatin, to see which is safer and more effective at lowering cholesterol in people with HIV who are on antiretroviral therapy. 86 participants with high cholesterol took one of the two drugs for 45 days. The goal was to manage …

This study looked at whether people with HIV who were already well-controlled on a regimen including enfuvirtide (an injectable drug) could safely switch to raltegravir (a pill). 170 participants were randomly assigned to either stay on enfuvirtide or switch to raltegravir. The m…

This study tested two versions of the H1N1 flu vaccine in 306 people with HIV to see which was safer and more effective. One vaccine included an immune booster (adjuvant), the other did not. The goal was to find the best way to protect this vulnerable group from the flu.

This study tested a low dose of interleukin-2 (IL-2) in 10 people with hepatitis C-related vasculitis that did not improve with standard treatments. The goal was to see if IL-2 could boost regulatory T cells to calm the immune system and reduce inflammation. Researchers monitored…

This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV who also have weak bones. About 140 participants received either alendronate or a placebo for two years, along with calcium and vitamin D. The main goal was to measure…

This study tested whether adding a powerful HIV drug called enfuvirtide (FUZEON®) to standard antiretroviral therapy could help people with HIV who also have a rare brain infection called progressive multifocal leukoencephalopathy (PML). PML is caused by the JC virus and typicall…

This study looked at whether adding vitamin D to the usual hepatitis C drugs (pegylated interferon and ribavirin) helps clear the virus in people who didn't respond to treatment before. 32 adults with chronic hepatitis C (genotype 1 or 4) and low vitamin D levels took part. The g…

This study tested whether adding an extra drug, enfuvirtide, to standard HIV therapy for 6 months could help severely ill patients recover their immune systems faster. It included 195 adults with HIV who had very low CD4 counts or a recent AIDS diagnosis and had never taken HIV d…

This study tested two different two-drug combinations in 61 adults with HIV who had not taken protease inhibitors before. The goal was to see if these combos could lower the virus to undetectable levels after 16 weeks. Researchers also watched for side effects and changes in body…

This study tested a combination of three drugs (pegylated interferon, ribavirin, and boceprevir) in 58 adults with genotype 1 hepatitis C and cirrhosis who were waiting for a liver transplant. The goal was to see if the treatment could clear the virus before transplant. Participa…

This study looked at whether adding a drug called Interleukin-2 (IL-2) to standard HIV treatment could help patients whose current therapy was failing and who had very low CD4 counts (below 200). The goal was to see if more patients could raise their CD4 counts above 200 after 52…

This study tested whether giving interleukin-2 (IL-2) injections to HIV patients who had never taken antiretroviral drugs could help keep their CD4 cell counts high and delay the need for standard HIV therapy. The trial enrolled 130 adults with CD4 counts between 300 and 500. Res…

This study tested whether HIV patients with long-term viral suppression could switch to a single drug (darunavir/r) instead of the standard two-drug regimen. 225 participants were followed for 48 weeks to see if the single drug could keep the virus undetectable. The goal was to s…

This study tested whether adding the drug maraviroc to standard HIV treatment for 24 weeks could improve immune function in people whose CD4 counts stayed low even though their HIV was well-controlled. The trial included 60 HIV-positive adults with CD4 counts below 350 and little…

This study surveyed 596 people in France who were recently diagnosed with HIV to find out why they didn't use PrEP, a medication that prevents HIV. Researchers asked about risky behaviors and whether participants were eligible for PrEP at the time of infection. The goal is to imp…

This study looked at 167 men who have sex with men and are on HIV treatment with undetectable virus in their blood. Researchers checked if the virus could still be found in their semen. The goal was to understand any remaining risk of passing HIV to a partner, even when blood lev…

This study looked at whether it's practical to offer rapid HIV testing to men who have sex with men (MSM) in community settings, rather than only at clinics. Researchers worked with teams in France and Canada to test this approach with 357 participants. The goal was to understand…